

- [79] Cheng MF, Chatterjee S, Berger NA. Schedule dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. *Oncol Res* 1994; 6: 269-79.
- [80] Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. *Cancer Res* 1991; 51: 1129-36.
- [81] Noda K, Nishiwaki Y, Kawahara M, *et al.* Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 2002; 346: 85-91.
- [82] Saylor RL III, Stine KC, Sullivan J, *et al.* Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. *J Clin Oncol* 2001; 19: 3463-69.
- [83] Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. *Clin Cancer Res* 2004; 10: 84-7.
- [84] Ando Y, Saka H, Ando M, *et al.* Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. *Cancer Res* 2000; 60: 6921-6.
- [85] Font A, Sanchez JM, Taron M, *et al.* Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. *Invest New Drugs* 2003; 21: 435-43.

---

Received: 22 September, 2004

Accepted: 8 October, 2004